STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

CURANEX PHARMACEUTICALS INC SEC Filings

CURX Nasdaq

Welcome to our dedicated page for CURANEX PHARMACEUTICALS SEC filings (Ticker: CURX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on CURANEX PHARMACEUTICALS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.

Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into CURANEX PHARMACEUTICALS's regulatory disclosures and financial reporting.

Rhea-AI Summary

Curanex Pharmaceuticals Inc. (CURX)$13.24M in net proceeds, plus $2.07M from the underwriters’ over-allotment exercise. As of September 30, 2025, the company held $5,830,537 in cash and had total assets of about $14.5M, driven largely by $8.47M of prepaid R&D with CROs and CDMOs.

The business remains pre-revenue and reported a net loss of $954,059 for the quarter and $1,151,988 for the nine months ended September 30, 2025, mainly from general and administrative costs of $466,863 and R&D expenses of $679,574. Management now concludes prior going concern doubts are alleviated based on IPO funding, though the company disclosed a Nasdaq notice on November 5, 2025 for its share price being below $1.00, with a compliance period through May 4, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
quarterly report
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other
-
Rhea-AI Summary

Curanex Pharmaceuticals (CURX) reported a Nasdaq notice that its common stock failed the $1.00 minimum bid price requirement for 30 consecutive business days. Trading on the Nasdaq Capital Market continues under “CURX”.

The company has a 180‑day compliance period until May 4, 2026 to regain compliance by having a closing bid of at least $1.00 for a minimum of ten consecutive business days (subject to Nasdaq staff discretion). If unmet, Curanex may receive an additional 180 days if it satisfies other initial listing standards and notifies Nasdaq of an intent to cure, which may include a reverse stock split. Failing that, the stock would be subject to delisting.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report

FAQ

What is the current stock price of CURANEX PHARMACEUTICALS (CURX)?

The current stock price of CURANEX PHARMACEUTICALS (CURX) is $0.435 as of December 5, 2025.

What is the market cap of CURANEX PHARMACEUTICALS (CURX)?

The market cap of CURANEX PHARMACEUTICALS (CURX) is approximately 12.6M.
CURANEX PHARMACEUTICALS INC

Nasdaq:CURX

CURX Rankings

CURX Stock Data

12.62M
9.12M
69.26%
0.42%
Biotechnology
Pharmaceutical Preparations
Link
United States
JERICHO